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HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CHILDREN: IM-
PROVED ENGRAFTMENT AND IMMUNE RECOVERY AFTER DEPLETION
OF T AND B CELLS INSTEAD OF POSITIVE SELECTION OF STEM CELLS?
Bader, P.1, Koehl, U.1, Soerensen, J.1, Lang, P.2, Kreyenberg, H.1,
Sach, G.1, Becker, M.1, Willasch, A.1, Esser, R.1, Handgretinger, R.2,
Klingebiel, T.1 1. University Children’s Hospital, Frankfurt am Main,
Germany; 2. University Children’s Hospital, Tuebingen, Germany.
During the past decade, transplantation of highly puriﬁed hap-
loidentical stem cells has become a well established treatment
procedure in the cure of many children with malignant and non-
malignant diseases. Positive enrichment of peripheral stem cells by
anti-CD34 or CD133 magnetic microbeads provides a graft pro-
foundly depleted of T and B cells facilitating engraftment without
inducing severe GVHD and EBV-lymphoproliferative disease. Al-
though transplanting “mega doses” (	106/kgBW) of positive en-
riched stem cells primary graft rejection, delayed immune recovery
and thereby an increased risk of transplant related mortality re-
mained major obstacles for the success of this approach. In 27
children with ALL who were transplanted with “mega-doses” (me-
dian: 16.46/kgBW; range 5.4–50.4) of positive enriched stem cells
from their HLA-haploidentical parents, primary engraftment
could be achieved in 88% and after reconditioning in 100% of
patients. All patients received G-CSF post transplant and achieved-
more than 500 ANC/l 12 days post transplant (range 8–24).
Immune recovery was obtained in all patients with a median time
to achieve more than 100 CD3 and CD4 cell/l of 67 and
101.2 days, respectively. Three year EFS of patients transplanted
in remission (n  21) was 0.43 ( 0.11). In contrast to positive
selection of stem cells, grafts after depletion of CD3/CD19 cells
consisted of remarkable amounts of effector cells such as NK-cells
(median number: 17.196/kgBW), dendritic cells, precursor T-cells,
and monocytes/granulocytes (median number: 446.456/kgBW).
These cells are expected to facilitate engraftment, speed up im-
mune reconstitution and provide also anti tumour activity in vivo.
So far nine children (ALL, n  4; AML, n  2; rhabdomyosar-
coma, n  2 and aplastic anaemia, n  1) were transplanted with
CD3/CD19 depleted peripheral stem cell grafts with a median
number of 10.66/kgBW CD 34 cells (range 4.6–20.0) at the
University Children’s Hospital Frankfurt. Without G-CSF, all
patients (100%) achieved rapid and sustained engraftment with
more than 500 ANC/l and more than 20.000 thrombocytes/l at
day 16.3 and 16.25, respectively. Median time to achieve more than
100 CD3 and CD4 cells/l was 53.0 and 52.5 days. Eight of
nine children are alive and well. One child with AML relapsed and
died on day 156 post transplant. Conclusions: Haploidentical
transplants using CD3/CD19 depleted grafts resulted in better and
more reliable engraftment with very rapid and potent immune
recovery.
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OUTCOME OF SECOND HEMATOPOIETIC STEM CELL TRANSPLANT IN
PEDIATRIC PATIENTS: A SINGLE INSTITUTION EXPERIENCE FROM
1975–2005
Cheng, J.C.1, Feig, S.A.1, Moore, T.B.1 1Mattel Children’s Hospital at
UCLA, Los Angeles, CA.
Purpose: To study the outcomes of second allogeneic hema-
topoietic stem cell transplant (HSCT) in pediatric patients for
malignant and non-malignant disorders. Furthermore, to iden-
tify predictors of favorable outcome in patients requiring second
HSCT. Methods: A retrospective analysis of 44 pediatric pa-
tients was performed studying recipients of a second allogeneic
HSCT from 1975–2005 at UCLA Medical Center. Twenty
patients with malignant disease (9 AML, 8 ALL, 2 CML, 1
Neuroblastoma) and 24 patients with non-malignant disease (14
severe aplastic anemia, 5 immunodeﬁciency, 5 other) were iden-
tiﬁed. Age, diagnosis, time to second transplant, graft-versus-
host disease severity, and conditioning regimen were studied as
possible predictors of favorable outcome. Results: The mean
age was 11.5 years (9.6 years for non-malignant group and 14.2
years for malignant group). The mean interval between trans-
plants was 12.3 months (20.5 for malignant, 5.6 for non-malig-
nant), 38/44 patients received 6/6 HLA-matched related do-
nors. A variety of conditioning regimens were used and GVHD
severity was variable. Survival to day 100 was comparable be-
tween malignant and non-malignant diseases (58% vs 56% re-
spectively; P  .84). However, despite a longer interval between
transplants, children with malignant diseases fared worse at 2
years (15% vs 42%; 95% CI: 2%–52%, P  .05). The leading
cause of death among patients with malignancies remained re-
lapsed disease. Age, GVHD severity and conditioning regimen
were not independently predictive of favorable outcome. Of
note, 5/5 matched unrelated donors did not survive after second
HSCT (2/5 preceded high-resolution typing availability). An
improvement in outcome over time was not appreciated. Con-
clusions: Second HSCT for pediatric patients remains associ-
ated with high morbidity and mortality. Similar to the adult
experience, children with non-malignant disease have improved
outcome after second transplant compared to relapsed malig-
nancy. There remain no clear predictors of favorable outcome
after second HSCT and despite improvements in supportive
care measures, outcomes remain poor. However, our experience
suggests that children who experience graft failure after initial
HSCT remain good candidates for second HSCT irrespective
of the time between transplants. Furthermore, careful consid-
eration should be given to justify the use of an unrelated donor
for second HSCT, as the outcome in our cohort or patients was
uniformly poor (Table 1).
Table 1. Survival After 2nd Allogeneic HSCT by Diagnosis




Anemia 5 9 50
ALL 4 4 50
AML 3 6 22
CML 1 1 0
Immunodeficiency 1 4 60
Other Non-
Malignant 4 3 33
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HIGH INCIDENCE OF GRAFT FAILURE AND TRANSPLANT RELATED
MORTALITY (TRM) IN 50 CHILDREN RECEIVING UNRELATED UMBIL-
ICAL CORD BLOOD TRANSPLANTATION (UCBT) FOR NON-MALIGNANT
DISEASES
Bonﬁm, C.1, Setubal, D.1, Bitencourt, M.1, Funke, V.1, Ruiz, J.1,
Koliski, A.2, Medeiros, C.R.1, Zanis-Neto, J.1, Pasquini, R.1 1. Federal
University of Parana, Curitiba, PR, Brazil; 2. Pediatric Intensive Care
Unit UFPR, Curitiba, PR, Brazil.
In countries with a high level of miscegenation, unrelated
umbilical cord blood is a rapidly available source of hematopoi-
etic stem cells for children with malignant and non-malignant
diseases who lack a suitable HLA identical sibling. We report
the results in 50 children with non-malignant diseases submitted
to UCBT in our BMT center between 07/97 and 04/05. Median
age: 6 years (20 days–14 years). Diseases: Fanconi Anemia (FA):
29 patients (pts); Primary Immunodeﬁciencies (PID): 10 pts
(Wiskott Aldrich: 6 pts. SCID: 3pts; Kostmann syndrome: 1pt);
Severe Aplastic Anemia: 2 pts, Blackfan-Diamond Anemia: 2
pts, Dyskeratosis congenita: 1 pt; Leukodystrophies: 2 pts; Os-
teopetrosis: 4 pts; HLA Disparities: 6/6: 9 pts; 5/6: 24 pts and
4/6: 17pts. The majority of pts received a combination of Busul-
fan  Cyclophosphamide (CY)  ATG:12 pts or CY  Flu-
darabine  ATG: 23 pts. Five pts received a TBI based prepa-
ratory regimen. Other regimens: 10 pts. GVHD Prophylaxis:
cyclosporine (csa)  steroids: 35 pts; csa methotrexate: 10 pts;
csa  MMF /- steroids: 5 pts. TNC (before thawing): 2, 3
20, 1  107/kg (M: 6, 1). Twenty-two pts are alive with a
median follow-up of 606 days (range 156–2684) UCBT (FA: 12
pts; PID: 8 pts; Osteopetrosis: 2 pts). Eight pts died before D
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